Tolmar’s Commitment to Patient Access

Tolmar is committed to responsible pricing and making our therapies accessible to patients in need. Our products hold favorable coverage positions across Medicare, Medicaid, state programs and commercial insurance carriers. 

Tolmar is dedicated to optimizing patient access to ELIGARD® (leuprolide acetate for injectable suspension) through our comprehensive benefit verification services and Patient Assistance Program (PAP).

Visit the ELIGARD® (leuprolide acetate for injectable suspension) website for additional information and resources supporting patient access to ELIGARD.